RevImmune

RevImmune is a privately held biotechnology company headquartered in France, the United States, and the United Kingdom, dedicated to developing CYT107 immunotherapy for infectious diseases and cancer. RevImmune is conducting multiple Phase II clinical trials using CYT107 for the treatment of sepsis, certain infectious diseases, and certain cancers. In RevImmune's previous trials for various viral diseases and sepsis, more than 440 patients have been treated with CYT107. In these trials, CYT107 demonstrated excellent safety and encouraging results.